Given the global epidemic of diabetes, targeted inhibition of CD146 may prevent both cancer occurrence in diabetics and the onset of diabetes in cancer patients, which will translate into a substantial socioeconomic benefit. This evidence concerns the gene MCAM and diabetes mellitus.